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INTRODUCTION 
 
Declining health in aging individuals reflects both the 
impaired function of a given organ, which in turn yields 
a disorder specific to that organ, as well as the 
breakdown of inter-organ communication networks 
controlled primarily by hormonal signals. The ovaries 
represent a classic example of both situations in that the 
female gonads serve as the source of not only germ cells 
(oocytes) needed for reproduction, but also a large 
number of bioactive factors that support or modulate the 
function of many other tissues and cells [1, 2].   
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Abstract: The female reproductive axis is the first major organ system of the body to fail with advancing age. In addition to
a permanent cessation of fertile potential, the loss of cyclic ovarian function in humans heralds the onset of menopause,
which in turn underlies the emergence of a diverse spectrum of health issues in aging women. Recently, it was reported
that bone marrow (BM) transplantation (BMT) into adult female mice conditioned a week earlier with highly cytotoxic
drugs rescues ovarian function and fertility. Herein we show in mice receiving no prior conditioning regimen that once‐
monthly infusions of BM‐derived cells retrieved from young adult female donors bearing an enhanced green fluorescent
protein  (EGFP)  transgene  sustain  the  fertile  potential  of  aging  wild‐type  females  long  past  their  time  of  normal
reproductive  senescence.  The  fertility‐promoting  effects  of  female  donor  BM  are  observed  regardless  whether  the
infusions are initiated in young adult or middle‐aged females. Although the mechanism by which BM infusions benefit the
reproductive performance of aging females remains to be elucidated, the absence of EGFP‐expressing offspring suggests
that it does not depend on development of mature eggs derived from germline‐committed cells in the donor marrow.
However, donor BM‐derived somatic cells accumulate in the recipients, indicating efficient donor cell engraftment without
prior  conditioning.  These  findings  provide  a  strong  impetus  to  further  explore  development  of  adult  stem  cell‐based
technologies to safely extend function of the female reproductive axis into advanced age without the need for toxic pre‐
conditioning protocols routinely used in other models of stem cell delivery.  
 
 
Unfortunately, the ovaries are the first major organs to 
fail in aging females, and this occurs long before age-
related dysfunction of other tissues is observed. For 
example, in women fertility becomes severely compro-
mised around the age of forty [3], preceding the meno-
pause by about a decade. Female mice exhibit a similar 
impairment of fertile potential approximately halfway 
through their chronological lifespan [4, 5]. Irrespective 
of the species evaluated, ovarian failure and the ensuing 
loss of fertility are driven by depletion and ultimate 
exhaustion of the oocyte-containing follicle reserve [6].  
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age-related ovarian failure sets the stage in aging 
females for markedly increased risks of developing a 
large number of debilitating health issues, including 
osteoporosis, cardiovascular disease and cognitive 
dysfunction [1]. In fact, recent studies in mice have 
solidified the direct causal association between ovarian 
failure and deteriorating health in females as they age. 
For example, inactivation of the pro-apoptotic Bax 
gene, which sustains the follicle pool and thus 
functional ovarian lifespan into very advanced age [7], 
extends fertile potential in aging females and minimizes 
the appearance of many age-related health problems, 
including bone and muscle loss, excess fat deposition, 
alopecia, cataracts, deafness, increased anxiety, and 
selective attention deficit [2]. Other studies have 
demonstrated that overall lifespan can be increased by 
transplanting young adult ovaries into aging female 
mice [8]. 
 
Despite the compelling nature of these findings, the fact 
that similar approaches are not feasible in humans has 
kept any possible clinical translation of this work 
uncertain. This may be on the verge of change, 
however, as new data suggest that ovarian function and 
fertility can be dramatically altered by technologies that 
might prove amenable for potential clinical 
development. The first of these data sets revolves 
around the surprising finding that the oocyte-containing 
follicle pool set forth at birth is, contrary to 
longstanding belief [9], replenished during adulthood by 
an as-yet unidentified population of presumptive female 
germline stem cells [10-13]. These findings have 
opened the possibility of developing new 
pharmacologic tools aimed at stimulating these cells to 
enhance oocyte formation when it might be clinically 
desirable, such as in females on the verge of 
reproductive failure [13, 14]. Other studies with mice 
have shown that approaches known to repress the 
insulin/insulin-like growth factor signaling pathway, 
such as moderate dietary caloric restriction (CR) 
initiated in adulthood [5] or chronic treatment with the 
anti-diabetic compound metformin [15], can 
dramatically extend cyclic ovarian function and fertility 
into very advanced ages. 
 
Regenerative medicine has also recently come into play 
in the context of female reproductive biology based on 
results showing that bone marrow (BM) transplantation 
(BMT) into chemotherapy-conditioned female mice 
generates a small number of donor-derived oocytes 
contained within immature follicles [11, 16] but does 
not yield mature (fertilization competent) donor-derived 
eggs [16, 17]. Similarly, spermatogonia, but not mature 
sperm, have been derived from BM of male mice [18, 
19] and men [20]. While these latter findings suggest 
that gametes arising from BM-derived cells exhibit a 
maturational defect, clinical studies have linked BMT to 
a return of gonadal function and fertility in some cancer 
survivors following high-dose chemotherapy [21-27]. 
These data and results from a recent study reporting a 
comparable rescue of long term-fertility in 
chemotherapy-treated female mice following BMT [16] 
further support that adult stem cell-based technologies 
may provide a novel means to restore or sustain 
reproductive organ function. Herein we tested in mice if 
once-monthly intravenous BM infusions (BM-INF), 
administered without prior radiation or chemotherapy 
conditioning, could delay age-related failure of the 
female reproductive axis. 
 
RESULTS 
 
Repeated BM-INF sustain natural fertility of 
aging females 
 
In initial experiments to examine the impact of BM-INF 
on function of the female reproductive axis with age, 
BM was harvested from young adult (6-10 weeks of 
age) female C57BL/6 donors and intravenously infused 
into non-conditioned female C57BL/6 recipients once 
every 4 weeks (n = 20). Thirteen of the recipients 
received BM collected from wild-type females, whereas 
the remaining 7 recipients received BM harvested from 
young adult transgenic donor females expressing 
enhanced green fluorescent protein (EGFP) under the 
control of a non-cell lineage-specific promoter [β -actin-
EGFP; JAX strain C57BL/6-Tg(ACTB-EGFP)1Osb/J]. 
Vehicle infusions (VEH-INF) into age-matched 
C57BL/6 females (n = 20) were performed in parallel. 
The infusions were initiated at 3 months of age, as past 
studies have shown that a significant decline in the 
primordial follicle pool in adult C57BL/6 female mice 
does not occur until after 100 days of age [12]. Hence, 
this design minimized the chance of a significant 
depletion of the follicle reserve in adulthood prior to 
initiation of the infusions. Furthermore, all females 
were mated to assure their fertility prior to initiation of 
the first infusions (data not shown). 
 
Between 3-8.5 months of age (prime reproductive life), 
VEH-INF (n = 20) and BM-INF (n = 20) females 
achieved a total of 56 and 59 full-term pregnancies, 
respectively, leading to the birth of offspring (data not 
shown). Between 8.5-11.5 months of age (transitional 
period leading up to reproductive failure), 19 remaining 
VEH-INF and 19 remaining BM-INF females delivered 
a total of 31 and 34 litters, respectively (Figure 1A). 
However, between 11.5-14 months of age (beginning of  
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reproductive failure), 30 full-term pregnancies were 
achieved by the 19 remaining BM-INF females, 
whereas only 23 full-term  pregnancies  were achieved  
by the 17 remaining VEH-INF females (Fig. 1A). 
Importantly, the two additional females that died in the 
VEH-INF group between 11.5-14 months of age had 
their last pregnancies at an approximately 8 months of 
age (data not shown). Thus, even if these two females 
were still present, it would be highly unlikely that they 
would have increased the total number of full-term 
pregnancies achieved by the VEH-INF females during 
this age bracket. The fertility of VEH-INF females 
declined even further between 14.5-17.5 months of age, 
with only 8 full-term pregnancies achieved by 16 
remaining females. In comparison, 17 remaining BM-
INF females delivered more than twice the number of 
litters between 14.5-17.5 months of age when compared 
with outcomes from the age-matched VEH-INF females 
(Figure 1A). Since the number of animals in each 
treatment group varied slightly with age, these data 
were re-calculated as a percentage of the total number 
of VEH-INF or BM-INF females that achieved full-
term pregnancies during the indicated age brackets. This 
analysis reaffirmed that repeated BM-INF improved the 
reproductive performance of aging females, particularly 
between 14.5-17.5 months of age (Figure 1B). 
 
 
 
 
 
 
Fertility is benefited irrespective of when the 
BM-INF are initiated  
 
The finding that repeated BM-INF sustained function of 
the female reproductive axis when the infusions were 
initiated early in adulthood (Figure 1) prompted us to 
examine whether fertility with age could be maintained 
if the infusions were initiated in females at the 
transitional period just prior to the onset of natural 
infertility. To test this, BM harvested from young adult 
β-actin-EGFP transgenic females or vehicle was infused 
into non-conditioned wild-type recipient females once 
every 4 weeks starting at 8 months of age, and mating 
trials were begun 2 months later. Between 10-11.5 
months of age, similar numbers of VEH-INF and BM-
INF females achieved full-term pregnancies (Figure 2A)  
However, for all subsequent mating attempts between 
11.5-17.5 months of age, 2-4 additional mice in BM-
INF group achieved full-term pregnancies when 
compared to the age-matched VEH-INF cohort (Fig. 
2B-E). Notably, and as will be discussed in more detail 
below, the number of offspring delivered by aging BM-
INF females that survived postnatally was consistently 
higher than survival rates of offspring delivered by age-
matched VEH-INF females (Figure 2B-E). Since a 
similar beneficial effect of BM-INF on reproductive 
capacity was observed irrespective of when in adult life 
the infusions were initiated, the results from the two 
trials were compiled and analyzed together as a 
percentage of females able to achieve full-term 
pregnancies in advanced ages (Figure 3). On average, 
76% of 8.5-11.5-month-old, 56% of 11.5-14.5-month-
old, and 31% of 14.5-17.5 month-old VEH-INF females 
remained fertile (Figure 3). In comparison, 82% of 8.5-
11.5-month-old, 75% of 11.5-14.5-month-old, and 52% 
of 14.5-17.5- month-old BM-INF females achieved full-
term pregnancies and delivered offspring (Figure 3). 
Figure  1.  Repeated  BM‐INF  delay  female  reproductive
aging. (A) Number of full‐term pregnancies achieved by female
mice at the indicated ages following once‐monthly infusions of
vehicle  (VEH‐INF)  or  BM  harvested  from  young  adult  female
donors (BM‐INF), initiated at 3 months of age. The total number
of  recipients  analyzed  in  each  age  bracket  is  indicated  in
parentheses over the respective bars. (B) Percentage of VEH‐INF
and  BM‐INF  females  that  achieved  full‐term  pregnancies
between  8.5‐11.5,  11.5‐14.5  and  14.5‐17.5  months  of  age,  as
calculated from the raw data shown in panel A. 
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Repeated BM-INF improve survival of offspring 
delivered by aged females  
 
During the entire mating period, females who received 
their first VEH or BM infusions at 3 months of age 
delivered a total of 765 and 849 offspring, respectively. 
Fecundity in both groups declined steadily with age 
from peak values of 7.8 ± 0.4 (VEH-INF) and 8.2 ± 0.3 
(BM-INF) pups per litter at the beginning of the mating 
trials (data not shown) to 3.5 ± 0.6 (VEH-INF) and 2.5 
± 0.4 (BM-INF) pups per litter during the final mating 
trials (14.5-17.5 months of age) (Fig. 4A). Similar 
outcomes were observed when the infusions were 
initiated at 8 months of age. A total of 126 and 185 
offspring were delivered by VEH-INF and BM-INF 
females, respectively, between 10-17.5 months of age. 
Fecundity fell from 7.9 ± 0.8 (VEH-INF) and 7.3 ± 0.6 
(BM-INF) pups  per litter at 10 months of  age to  3.4  ±  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.  Reproductive  performance  of  aging  female
mice  after  once‐monthly  infusions  of  vehicle  or  BM
harvested from young adult female donors, initiated at 8
months of age. Fertility outcomes are shown for each VEH‐INF
female and BM‐INF female between 10‐11.5 (A), 11.5‐13 (B), 13‐
14.5 (C), 14.5‐16 (D), and 16‐17.5 (E) months (M) of age (each
mouse is represented by a number on the x‐axis) run in parallel
mating trials. The total number of offspring delivered and that
survived for each female are indicated. Crosses designate mice
that had to be euthanized due to severe health complications or
that died of natural causes during the study period. 
 
0.8 (VEH-INF) and 3.8 ± 0.6 (BM-INF) pups per litter 
between 14-17.5 months of age (Fig. 4B). While no 
differences in fecundity were detected among the 
treatment groups, a striking difference in postnatal 
offspring survival was observed. Only 33% of the 42 
offspring delivered by 13-17.5-month-old VEH-INF 
females survived after delivery, whereas 71% of the 86 
pups delivered by age-matched BM-INF survived (Fig. 
4C). Of final note, all offspring delivered by females 
infused with BM from β-actin-EGFP donors (n = 512) 
were genotyped and found to be derived from the 
recipient germline (data not shown). 
 
Chimerism analysis of the infused recipients  
 
Donor cell tracking in the ovaries of females infused 
with BM from β-actin-EGFP donors was performed at 
the conclusion of the mating trials, and showed little 
evidence of EGFP-positive cell engraftment (Fig. 5A-C).  
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Unfortunately, the advanced age of the females from 
which the ovaries were collected precluded in-depth 
analysis of germline chimerism, as has been reported 
for the ovaries of young adult chemotherapy-
conditioned mice following stem cell transplantation 
[11, 16]. Analysis of wild-type recipient BM by flow 
cytometry at the end of the mating trials (4 weeks after 
the last infusion) showed 7.6 ± 1.3% EGFP chimerism 
(n = 4, Fig. 5D). The EGFP-positive cells found in the 
BM of once-monthly-infused female recipients at the 
end of the experiments (15 infusions total) were 
unlikely to represent only cells from the last infusion, as 
a single infusion of cells derived from BM of β-actin-
EGFP donors into non-conditioned wild-type recipients 
resulted in 0.8 ± 0.2% chimerism 2-4 weeks later (n = 4; 
Fig. 5D). For comparison, engraftment of EGFP-
positive BM-derived cells was additionally analyzed in 
female recipients conditioned with combination 
chemotherapy (busulfan plus cyclophosphamide) 1 
week prior to BMT, as previously detailed [11, 16]. 
Under these conditions, 3.3 ± 0.2% (n = 4) and 8.4 ± 
3.1% (n = 4) of the total recipient BM-derived cell 
population was found to be EGFP-positive at 2 and 4 
weeks post-BMT, respectively (Fig. 5D). 
 
DISCUSSION 
 
As human life-expectancy continues to trend upward, 
biomedical  research  directed  at  promoting improved 
health and well-being in aging individuals has become 
an increasingly relevant and widespread area of  scien- 
 
 
Figure  3.  Pooled  analysis  of  the  effects  of  BM‐INF  on
reproductive function in aging females. Percentage of VEH‐
INF and BM‐INF females that achieved full‐term pregnancies at
the  indicated  ages,  as  calculated  from  the  combined  raw  data
shown  in  figure  1A  (infusions  started  at  3 months  of  age)  and
figure  2  (infusions  started  at  8  months  of  age).  A  significantly
(Fisher’s  exact  test)  higher  percentage  of  BM‐INF  females
achieved full‐term pregnancies between 11.5‐14.5 and 14.5‐17.5
months of age compared with age‐matched VEH‐INF females.
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4. Repeated  BM‐INF  do  not  affect  fecundity  but
dramatically improve survival rates of offspring delivered by
aging females. Summary of fecundity (mean ± SEM) of female mice
that  achieved  full‐term  pregnancies  at  the  indicated  ages  following
once‐monthly  infusions  of  vehicle  (VEH‐INF)  or  BM  harvested  from
young  adult  female  donors  (BM‐INF),  starting  at  3 months  (A)  or  8
months (B) of age. (C) Offspring number and survival rates in mating
trials of VEH‐INF or BM‐INF females between 10‐17.5 months of age
following  once‐monthly  infusions  initiated  at  8  months  of  age.  In
addition  to  a  marked  increase  in  the  total  number  of  offspring
delivered,  the  number  of  offspring  delivered  that  survived  was
significantly increased by BM‐INF (*, P = 0.0001 versus the VEH‐INF
group by Fisher’s exact test).
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increasing interest has been placed on the possible use 
of regenerative medicine and adult stem cells, 
particularly those derived from BM, in combating age-
related deterioration of organs and tissues. Much of our 
current understanding of adult stem cell biology in this 
regard, however, derives from studies in which stem or 
progenitor cells were tested for their ability to improve 
organ function in disease, injury, or insult models [16, 
29-33] or from in vitro studies in which BM-derived 
cells have been shown to differentiate into variety of 
cell types [33, 34]. Thus, although a wealth of general 
information regarding the plasticity of BM-derived and 
other adult stem cells is available, very little is known 
of the potential utility of such cells to actually combat 
various aspects of physiological aging in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The female reproductive axis provides an excellent 
model for understanding age-related organ 
degeneration, as the ovaries undergo functional decline 
and failure relatively early in life, long before possible 
confounding influences from aging of the other tissues 
and organs [1, 3]. Thus, in this study we used the female 
reproductive system as a model to investigate whether 
physiological decline in organ function with age could 
be postponed by in vivo delivery of cells harvested from 
young adult BM, which is known to be a rich source of 
stem cells. Our results show that once-monthly 
infusions of adult BM-derived cells into recipient 
female mice that received no prior cytotoxic 
conditioning regimen sustain the function of the female 
reproductive axis into advanced chronological age. 
Further, the improvements in reproductive performance 
with age were observed regardless of whether the 
infusions were initiated early in adult life (3 months of 
age) or in mid-adult life just prior to the decline in 
reproductive function (8 months of age). Interestingly, 
however, females receiving their first BM-INF at 8 
months of age that were infertile from the beginning of 
mating attempts at 10 months of age were not able to 
regain their fertility. These findings indicate that BM-
derived cells from young donors are effective at 
sustaining reproductive organ function only if 
administered at an age when the target tissue(s) is still 
functional. 
 
 
The mechanisms by which the infusions of young adult 
BM cells into females postpone age-related infertility 
remain to be elucidated. While our previous studies 
with mice have shown that transplanted BM-derived 
cells can differentiate into immature oocytes and rescue 
long-term fertility of chemotherapy-treated recipient 
females [16], in this study we did not detect a 
significant level of donor cell chimerism (somatic or 
germline) in the ovaries of the recipients at the 
conclusion of the mating trials. Moreover, all of the 
offspring delivered by females infused with BM from β-
actin-EGFP-transgenic donors were wild-type and thus 
derived from the recipient germline. Although these 
data suggest that the infused BM-derived cells 
indirectly impact on the function of the female gonads 
with age, it is equally possible that EGFP chimerism in 
recipient ovaries was extremely low due to the 
advanced age of the tissue at the time of assessment. It 
has also recently been proposed from studies with rats 
that BM-derived cells secrete a variety of cytokines 
which improve ovarian function in recipient females 
after cytotoxic insult by, at least in part, reducing 
apoptosis in ovarian somatic cells [35]. If a similar 
situation exists in the non-insult model of aging, 
secreted factors from repeatedly infused young adult 
BM-derived cells could act as anti-apoptotic signals in 
Figure  5.  Analysis  of  donor  cell  engraftment  in  recipients
after  BM‐INF  without  prior  conditioning.  Representative
immunohistochemical analysis of EGFP expression (brown) in ovaries
of aged wild‐type females following 15 once‐monthly infusions of
BM  harvested  from  young  adult β ‐actin‐EGFP  transgenic  female
donors (A, B). The ovary of a representative transgenic donor female
(C) is shown as a positive control. (D) Chimerism analysis of BM‐
derived cells collected from female mice following 15 once‐monthly
infusions of β‐actin ‐EGFP transgenic BM (BM‐INF, X15) or a single
infusion  of β ‐actin‐EGFP  transgenic  BM  (BM‐INF,  X1).  Parallel
analysis of BM harvested from recipient females conditioned with
busulfan and cyclophosphamide prior to BMT (again using β‐actin‐
EGFP transgenic females as donors) is shown for comparison. For
these samples, BM was collected 2 weeks (wk) and 4 weeks post‐
BMT. The data shown represent the mean ± SEM of results from
analysis of 4 mice per group. 
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reactivation of stem cells in aging target tissues. While a 
case for the latter has recently been made from studies 
of improved muscle regeneration in aged mice after 
parabiotic blood exchange with younger but not aged 
animals [36], we have found in the chemotherapy model 
of induced ovarian failure [16] that BM harvested from 
male mice does not possess the same pro-fertility effects 
of transplanted female donor BM (Figure 6). Assuming 
there is no gender-specific difference in the ability of 
BM-derived cells to secrete various cytokines and other 
bioactive factors, these data suggest another mechanism 
underlies the fertility outcomes observed herein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whatever the case, the most striking, and to us 
unexpected, result of the repeated BM-INF was the 
dramatic improvement in the survival rates of pups 
delivered by aged females. Although fecundity (pups 
born per litter) was unaffected by BM-INF, the survival 
of offspring born to 13-17.5-month-old BM-INF 
recipients was far superior when compared to that of 
offspring delivered by age-matched VEH-INF females. 
To our knowledge, this is one of the first examples of an 
experimental approach conveying such an effect, other 
than moderate CR initiated in females during adulthood 
[5]. As is the case with the CR model, these results 
could be explained by one of several not mutually 
exclusive possibilities. The most logical is an 
improvement in the overall quality of eggs in aging 
females, since age-related deterioration in egg quality 
represents one of the most cumbersome issues faced by 
women of advanced maternal age trying to become 
pregnant [37, 38]. It is also possible that non-ovarian 
target tissues of the aging female reproductive axis, 
such as the uterus where the embryo implants to form a 
placenta for fetal gestation, are benefited by repeated 
BM-INF. In support of this, recent studies of human 
females that received allogeneic BMT demonstrated the 
presence of donor-derived cells in the uterus of the 
recipients, albeit at low numbers [39, 40]. Although 
more work is needed to fully understand the 
mechanisms at work, these findings support continued 
development of cell transplantation-based technologies 
to safely extend ovarian function and fertility of aging 
females. Furthermore, while much speculation exists 
regarding the potential for regenerative medicine to 
combat age-related organ failure, this study provides 
important proof-of-concept that such an outcome can 
actually be achieved and can be done without the need 
for toxic conditioning protocols used in other models of 
in-vivo BM or adult stem cell delivery. 
 
 
METHODS 
 
Animals. Wild-type 8-month-old C57BL/6 female mice 
were obtained from Taconic (Germantown, NY), 
whereas all young adult C57BL/6 female mice and 
C57BL/6 male mice were purchased from The Jackson 
Laboratories (Bar Harbor, ME). Breeding pairs of 
transgenic mice with EGFP expression driven by the 
chicken  β-actin promoter were obtained from The 
Jackson Laboratories [JAX strain C57BL/6-Tg(ACTB-
EGFP)1Osb/J]. All animal procedures reported herein 
were reviewed and approved by the institutional animal 
care and use committee of Massachusetts General 
Hospital.  
Figure  6.  Male  donor  BM  does  not  replicate  the  pro‐
fertility effects of female donor BM. Percentage of female
mice receiving vehicle (Control, n = 18), a combination chemo‐
therapy regimen containing busulfan and cyclophosphamide (CTx,
n = 21) or CTx followed by bone marrow transplantation 1 week
later, using young adult male (MBMT, n = 16) or female (FBMT, n
=  19)  donors,  that  achieved  full‐term  pregnancies  over  a
subsequent 7‐month period when mating was initiated coincident
with  the  transplants.  Data  shown  are  the  mean  ±  SEM  of
combined results from 3 separate trials (*, P < 0.05 versus the
respective CTx group or CTx + MBMT group).   
Bone marrow infusions. Bone marrow was harvested 
from the femurs and tibias of female donor mice just 
prior to the infusions. Bones were cleaned and then 
crushed with a mortar and pestle in cold 1X-phosphate 
buffered saline (PBS). The cells were then passed 
through a 40-μm-filter, centrifuged and resuspended in 
ACK Lysing Buffer (Fisher Scientific, Pittsburgh, PA) 
for red blood cell lysis. The cells were centrifuged, 
washed and resuspended in cold PBS. Once isolated, 
1.5-3X10
7 mononuclear cells (in 0.25 ml) were injected 
into recipients via the lateral tail vein as described [11, 
16], with the exception that the recipients were not 
conditioned with chemotherapy beforehand. Infusions 
were initiated at 3 or 8 months of age, and repeated 
every 4 weeks for the duration of the study. For single 
BM-INF, 1.5-3X10
7 cells derived from BM of β-actin-
EGFP mice were infused into 8-week-old C57BL/6 
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collected 2-4 weeks later for chimerism analysis. 
 
Fertility testing (mating trials). All females whose in-
fusions were initiated at 3 months of age were mated 
prior to the first infusion to assure fertility. For 
outcomes analysis, mating trials were initiated at 3 or 10 
months of age under a paired breeding arrangement 
housing two females and one male of proven fertility in 
each cage. Males were randomly rotated among the 
cages during the mating trials [5]. The total number of 
offspring delivered per litter and the number of 
offspring delivered that survived were recorded 
separately for each pregnancy. Pups that did not survive 
were either found dead at birth or died very shortly after 
delivery. All viable offspring were allowed to remain 
with the dam until weaning, at which time the offspring 
were removed from the cages to allow for a subsequent 
mating attempt with the dam. For all offspring that 
survived, no anatomical or health complications were 
observed (data not shown). 
 
Bone marrow transplantations. Eight-week-old C57BL/6 
female mice were chemotherapy conditioned using 12 
mg/kg busulfan (Sigma, St. Louis, MO) and 120 mg/kg 
cyclophospamide (Cytoxan; Bristol-Meyers Squibb, New 
York, NY), as described [11, 16].  For cell trac-king 
experiments, 1 week post-cytotoxic drug treatment each 
female received a tail vein injection of vehicle or 1.5-
3X10
7 BM-derived cells from young adult β-actin-EGFP 
donor females. Recipients were euthanized at 2 and 4 
weeks post-transplantation, and BM was har-vested and 
processed for flow cytometric analysis of EGFP chime-
rism. For fertility testing, 1 week post-cytotoxic drug 
treatment each female received a tail vein injection of 
vehicle or 1.5-3X10
7 BM-derived cells from young adult 
(8-10 weeks of age) wild-type male or female donors, 
and mating trials were conducted as described [16]. 
 
Donor cell tracking and EGFP chimerism in BM.  For 
donor cell tracking, recipient ovaries were fixed in 4% 
paraformaldehyde, embedded in paraffin and sectioned 
for analysis using a GFP-specific antibody (sc-9996; 
Santa Cruz Biotechnology, Santa Cruz, CA), as detailed 
previously [11, 16]. Positive and negative controls 
consisting of ovarian tissue from β-actin-EGFP 
transgenic females and wild-type C57BL/6 females, 
respectively, were analyzed in parallel on the same slides. 
 
Bone marrow-derived cell preparations from the 
indicated experimental groups were prepared as detailed 
above for the BM infusions. After the last PBS wash, the 
cells were resuspended in cold PBS containing 1 µg/ml 
propidium iodide (Invitrogen, Carlsbad, CA) for exclusi-
on of necrotic cells from the analysis. Live BM cells 
were analyzed for EGFP expression with a flow 
cytometer (FACSaria, BD Biosciences) at the Harvard 
Stem Cell Institute Flow Cytometry Core  Facility 
(Massachusetts General Hospital, Center for 
Regenerative Medicine, Boston, MA), as described 
previously [16]. As controls, BM samples from VEH-
INF wild-type females, non-transplanted wild-type 
females and β-actin-EGFP transgenic females were 
analyzed in parallel (data not shown). 
 
Data presentation and analysis. Graphs depict results 
from each individual mouse or combined data from the 
independent trials. Where appropriate, combined data 
were analyzed by Fisher’s exact test or Student’s t-test 
(GraphPad Prism software, version 4.0; San Diego, CA) 
for statistical comparisons of results between 
experimental groups. 
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